Literature DB >> 17890275

The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

A M Huber1, E M Dugan, P A Lachenbruch, B M Feldman, M D Perez, L S Zemel, C B Lindsley, R M Rennebohm, C A Wallace, M H Passo, A M Reed, S L Bowyer, S H Ballinger, F W Miller, L G Rider.   

Abstract

OBJECTIVES: Clinical care and therapeutic trials in idiopathic inflammatory myopathies (IIM) require accurate and consistent assessment of cutaneous involvement. The Cutaneous Assessment Tool (CAT) was designed to measure skin activity and damage in IIM. We describe the development and inter-rater reliability of the CAT, and the frequency of lesions endorsed in a large population of juvenile IIM patients.
METHODS: The CAT includes 10 activity, 4 damage and 7 combined lesions. Thirty-two photographic slides depicting IIM skin lesions were assessed by 11 raters. One hundred and twenty-three children were assessed by 11 paediatric rheumatologists at 10 centres. Inter-rater reliability was assessed using simple agreements and intra-class correlation coefficients (ICC).
RESULTS: Simple agreements in recognizing lesions as present or absent were generally high (0.5-1.0). ICCs for CAT lesions were moderate (0.4-0.75) in both slides and real patients. ICCs for the CAT activity and damage scores were 0.71 and 0.81, respectively. CAT activity scores ranged from 0 to 44 (median 7, potential range 0-96) and CAT damage scores ranged from 0 to 13 (median 1, potential range 0-22). The most common cutaneous lesions endorsed were periungual capillary loop changes (63%), Gottron's papules/sign (53%), heliotrope rash (49%) and malar/facial erythema (49%).
CONCLUSIONS: Total CAT activity and damage scores have moderate to good reliability. Assessors generally agree on the presence of a variety of cutaneous lesions. The CAT is a promising, semi-quantitative tool to comprehensively assess skin disease activity and damage in IIM.

Entities:  

Mesh:

Year:  2007        PMID: 17890275      PMCID: PMC2598780          DOI: 10.1093/rheumatology/kem179

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

Authors:  Rita K Bode; Marisa S Klein-Gitelman; Michael L Miller; Toula S Lechman; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-02-15

3.  Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.

Authors:  Rachel Lynne Smith; Joyce Sundberg; Eli Shamiyah; Alan Dyer; Lauren M Pachman
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

4.  The self-administered psoriasis area and severity index is valid and reliable.

Authors:  S R Feldman; A B Fleischer; D M Reboussin; S R Rapp; M L Exum; A R Clark; L Nurre
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

Review 5.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Nicolino Ruperto; Angelo Ravelli; Kevin J Murray; Daniel J Lovell; Boel Andersson-Gare; Brian M Feldman; Stella Garay; Wietse Kuis; Claudia Machado; Lauren Pachman; Anne-Marie Prieur; Lisa G Rider; Earl Silverman; Elena Tsitsami; Pat Woo; Edward H Giannini; Alberto Martini
Journal:  Rheumatology (Oxford)       Date:  2003-06-27       Impact factor: 7.580

6.  Severe psoriasis--oral therapy with a new retinoid.

Authors:  T Fredriksson; U Pettersson
Journal:  Dermatologica       Date:  1978

Review 7.  Skin involvement in dermatomyositis.

Authors:  Beth Santmyire-Rosenberger; Elizabeth M Dugan
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

8.  Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

Authors:  Adam M Huber; Brian M Feldman; Robert M Rennebohm; Jeanne E Hicks; Carol B Lindsley; Maria D Perez; Lawrence S Zemel; Carol A Wallace; Susan H Ballinger; Murray H Passo; Ann M Reed; Ronald M Summers; Patience H White; Ildy M Katona; Frederick W Miller; Peter A Lachenbruch; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2004-05

9.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

Review 10.  Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics.

Authors:  Richard D Sontheimer
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

View more
  19 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

3.  Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.

Authors:  Adam M Huber; Peter A Lachenbruch; Elizabeth M Dugan; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-03-15

4.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

5.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

Review 6.  The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.

Authors:  S Ahmed; K L Chen; V P Werth
Journal:  Semin Arthritis Rheum       Date:  2020-01-11       Impact factor: 5.532

7.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Authors:  Adam M Huber; Edward H Giannini; Suzanne L Bowyer; Susan Kim; Bianca Lang; Carol B Lindsley; Lauren M Pachman; Clarissa Pilkington; Ann M Reed; Robert M Rennebohm; Lisa G Rider; Carol A Wallace; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

Review 8.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

9.  Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Authors:  R Q Klein; C A Bangert; M Costner; M K Connolly; A Tanikawa; J Okawa; M Rose; S S Fakharzadeh; D Fiorentino; L A Lee; R D Sontheimer; L Taylor; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2008-07-04       Impact factor: 9.302

Review 10.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.